var data={"title":"Betamethasone (topical): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Betamethasone (topical): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/718350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=betamethasone-topical-drug-information\" class=\"drug drug_general\">see &quot;Betamethasone (topical): Drug information&quot;</a> and <a href=\"topic.htm?path=betamethasone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Betamethasone (topical): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AlphaTrex [DSC];</li>\n      <li>Diprolene;</li>\n      <li>Diprolene AF;</li>\n      <li>Luxiq;</li>\n      <li>Sernivo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Betaderm;</li>\n      <li>Beteflam;</li>\n      <li>Betnesol;</li>\n      <li>Celestoderm V;</li>\n      <li>Celestoderm V/2;</li>\n      <li>Diprolene;</li>\n      <li>Diprosone;</li>\n      <li>Luxiq;</li>\n      <li>Prevex B;</li>\n      <li>Rivasone;</li>\n      <li>Rolene;</li>\n      <li>Rosone;</li>\n      <li>Valisone Scalp Lotion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168324\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Topical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168330\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=betamethasone-topical-drug-information\" class=\"drug drug_general\">see &quot;Betamethasone (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid HPA axis suppression. <b>Note:</b> Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Dermatoses (corticosteroid-responsive):</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Betamethasone valerate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream/ointment: Children and Adolescents: Apply a thin film to the affected area once to 3 times daily; usually once or twice daily application is effective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lotion: Children and Adolescents: Apply a few drops to the affected area twice daily; in some cases, more frequent application may be necessary; following improvement reduce to once daily application</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Betamethasone dipropionate (augmented formulation): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream/ointment: Adolescents: Apply a thin film to affected area once or twice daily; maximum dose: 50 g/week; evaluate continuation of therapy if no improvement within 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel: Children and Adolescents &ge;12 years: Apply a thin layer to the affected area once or twice daily; rub in gently; maximum dose: 50 g/week; not recommended for use longer than 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lotion: Adolescents: Apply a few drops to the affected area once or twice daily; rub in gently; maximum dose: 50 <b>mL</b>/week; not recommended for use for longer than 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily. Maximum dose: 50 g/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, unaugmented formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone valerate 0.1%: Apply 1 to 3 times daily.<b> Note: </b>Once- or twice-daily applications are usually effective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Apply to the scalp twice daily, once in the morning and once at night. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel, augmented formulation: Apply once or twice daily; rub in gently. Maximum: 50 g/week. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lotion, augmented formulation: Betamethasone dipropionate 0.05%: Apply a few drops once or twice daily.  Maximum dose: 50 mL/week. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lotion, unaugmented formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone dipropionate 0.05%: Apply a few drops twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone valerate 0.1%: Apply a few drops twice daily; may consider increasing dose for resistant cases. Following improvement, may apply once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily. Maximum dose: 50 g/week. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment, unaugmented formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Betamethasone valerate 0.1%: Apply 1 to 3 times daily. <b>Note:</b> Once- or twice-daily applications are usually effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plaque psoriasis: </b>Spray, unaugmented formulation: Betamethasone dipropionate 0.05%: Topical: Apply twice daily for up to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780990\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene AF: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sernivo: 0.05% (120 mL) [contains cetostearyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Foam, External, as valerate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Luxiq: 0.12% (50 g, 100 g) [contains alcohol, usp, cetyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.12% (50 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaTrex: 0.05% (15 g [DSC], 50 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene: 0.05% (30 mL, 60 mL) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (30 mL, 60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780936\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168331\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: For external use only. Apply sparingly to affected areas. Not for use on broken skin or in areas of infection. Do not apply to wet skin unless directed; do not cover with occlusive dressing. Do not apply very high potency agents to face, groin, axillae, or diaper area.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betamethasone dipropionate spray: Spray directly onto affected areas (spray only enough to sufficiently cover the area); rub in gently and wash hands after applying. Shake well before use. Do not use if atrophy is present at the treatment site. Do not cover with occlusive dressing unless directed otherwise by health care provider. For topical use only; not for oral, ophthalmic, or vaginal use; avoid use on the face, scalp, axilla, groin, or other intertriginous areas.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betamethasone valerate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Invert can and dispense a small amount onto a saucer or other cool surface. Do not dispense directly into hands as foam will begin to melt immediately upon contact with warm skin. Pick up small amounts of foam and gently massage into affected areas until foam disappears. Repeat until entire affected scalp area is treated. Avoid fire, flame, and/or smoking during and immediately following application.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lotion: Shake well prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25090737\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, lotion, ointment, spray: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard any unused spray after 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Avoid fire, flame, or smoking during use. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 49&deg;C (120&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch [Canadian product]: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Use immediately after opening sachet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168325\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betamethasone dipropionate (augmented): Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the skin (Cream, lotion, and ointment: FDA approved in ages &ge;13 years and adults; Gel: FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betamethasone dipropionate spray: Treatment of mild to moderate plaque psoriasis (FDA approved in ages &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betamethasone valerate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream, lotion, and ointment: Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the skin (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Foam: Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the scalp including psoriasis (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780928\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Luxiq may be confused with Lasix</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23781007\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Tingling (paresthesia at application site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption, alopecia, dermatitis, pruritus, skin atrophy (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: HPA axis suppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site reactions (includes burning, stinging, and itching; most reactions were mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Atrophic striae, bullous dermatitis, capillary fragility, contact dermatitis, dermal ulcer (of psoriatic lesions), dyshidrotic eczema, eczema, edema, epidermolysis, exacerbation of psoriasis, herpes zoster, hirsutism, hypersensitivity reaction, pain, skin hypertrophy, skin infection (application site)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780949\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to betamethasone, other corticosteroids, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, Lotion: Untreated bacterial, tubercular, and fungal skin infections; viral diseases (eg, herpes simplex, chicken pox, vaccinia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Treatment of rosacea, acne vulgaris, perioral dermatitis, or pruritus without inflammation (foam); skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations; application to eyes (foam); &lt;18 years of age (patch). <b>Note:</b> Product labels may vary (refer also to product labels).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780950\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to varicella zoster (chickenpox) should be avoided; corticosteroids should not be used to treat ocular herpes simplex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Discontinue if skin irritation or contact dermatitis occurs; do not use in patients with decreased skin circulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome (rare), hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, application to large surface areas, or prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of augmented formulations in patients &lt;13 years of age is not recommended. For all formulations, children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients. Use lowest dose possible for shortest period of time to avoid HPA axis suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; adverse effects may be increased. In the presence of a fungal or bacterial dermatologic infection, institute appropriate antifungal or antibacterial therapy. If the infection does not resolve promptly, discontinue use until the infection has been adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Augmented (eg, very high potency) products: Use of augmented formulations in patients &lt;13 years of age is not recommended. Not for treatment of rosacea, perioral dermatitis, or if skin atrophy is present at treatment site; not for facial, groin, axillary, oral, ophthalmic, or intravaginal use; not for use in a diapered area. Avoid concurrent use of other corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flammable contents: Foam contains flammable propellants. Avoid fire, flame and smoking during and immediately following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patch [Canadian product]: Has not been studied in psoriasis of the face, scalp or intertriginous areas; contains methyl and propyl parahydroxybenzoate, which may cause hypersensitivity (sometimes delayed).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose by reducing the frequency of application or substitution of a less potent steroid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820008\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The extent of percutaneous absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Infants and small children may be more susceptible to HPA axis suppression, intracranial hypertension, Cushing syndrome, or other systemic toxicities due to larger skin surface area to body mass ratio. HPA axis suppression was observed in 32% of infants and children (age range: 3 months to 12 years) being treated with betamethasone dipropionate cream (0.05%) for atopic dermatitis in an open-label trial (n=60); the incidence was greater younger patients vs older children (mean reported incidence for age ranges: &le;1 year: 50%; 2 to 8 years: 32% to 38%; 9 to 12 years: 17%). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23781009\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23781008\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95149&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780945\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780946\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic dermatitis in pregnant women; high potency corticosteroids are not recommended during the first trimester. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Bae 2011; Koutroulis 2011; Leachman 2006). Refer to the Betamethasone systemic monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168332\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth in pediatric patients; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780956\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Betamethasone has intermediate to very high range potency (dosage-form dependent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780958\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical corticosteroids are absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and bile</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24168333\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Very high potency (super high potency): Augmented betamethasone dipropionate ointment, lotion, gel </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High potency: Augmented betamethasone dipropionate cream, betamethasone dipropionate cream and ointment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermediate potency: Betamethasone dipropionate lotion, betamethasone valerate cream </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780992\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $38.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $44.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (45 g): $45.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Diprolene AF External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $102.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Sernivo External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (120 mL): $982.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.12% (50 g): $326.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Luxiq External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.12% (50 g): $537.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $61.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 mL): $75.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 mL): $46.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Diprolene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 mL): $117.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $63.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $50.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $20.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Diprolene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $108.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24799714\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allerkan (PH);</li>\n      <li>Antroquoril (AU);</li>\n      <li>Bacort (PY);</li>\n      <li>Beavate (MY);</li>\n      <li>Beisong (CN);</li>\n      <li>Beloderm (HR, SK);</li>\n      <li>Bemon (DE);</li>\n      <li>Benosone (MY);</li>\n      <li>Beprogel (HK, SG, TH);</li>\n      <li>Bepronate (TH);</li>\n      <li>Beprosone (HK, ID, PH, SG, TH);</li>\n      <li>Besone (MY, TH);</li>\n      <li>Beta (NZ);</li>\n      <li>Betacort (PK);</li>\n      <li>Betacorten (IL);</li>\n      <li>Betaderm (LK, RO, SA, VE);</li>\n      <li>Betaduo (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Betagalen (DE);</li>\n      <li>Betaleb (LK);</li>\n      <li>Betamed (AE);</li>\n      <li>Betamousse (IE);</li>\n      <li>Betasone (HK, KW, LB, SA, ZW);</li>\n      <li>Betaval (BH, JO);</li>\n      <li>Betazon (BG);</li>\n      <li>Betesil (GB);</li>\n      <li>Betnelan (NL, QA);</li>\n      <li>Betneval (FR);</li>\n      <li>Betnikit (LK);</li>\n      <li>Betnoderm (PH, SE);</li>\n      <li>Betnovat (DK, IS, LT, NO, SE);</li>\n      <li>Betnovate (AE, AT, AU, BG, BH, BR, CH, CL, CY, CZ, EE, ES, GB, GR, HK, IE, IL, IN, JO, KW, LB, LK, MT, MX, NZ, PH, PL, PT, QA, SA, SG, TH, TR, UY, VE, VN);</li>\n      <li>Bettamousse (IL);</li>\n      <li>Camnovate (SG);</li>\n      <li>Celestoderm (FR);</li>\n      <li>Clinivate (TH);</li>\n      <li>Cortiderm (IN);</li>\n      <li>Cortival (AU);</li>\n      <li>Cremirit (CL);</li>\n      <li>Denvercort (AR);</li>\n      <li>Dermasone (SG);</li>\n      <li>Dermisole (LK);</li>\n      <li>Dermocort (BG);</li>\n      <li>Derzid (HK, SG);</li>\n      <li>Di An Song (CN);</li>\n      <li>Diprobet (LK);</li>\n      <li>Diprocel (HK, MY);</li>\n      <li>Diproderm (AT, DK, ES, FI, IS, NO, SE);</li>\n      <li>Diproforte (AT);</li>\n      <li>Diprolen (CH, DK, FI);</li>\n      <li>Diprolene (AE, BB, BE, BH, FR, JO, KW, NL, PH, PK, PL, QA, SA, TR);</li>\n      <li>Diprosone (AU, BE, BG, BH, BR, CO, CZ, DE, EG, FR, GB, HK, IT, JO, KW, LB, LU, MY, NL, NZ, PE, PH, PT, PY, QA, SA, SI, TH, VN);</li>\n      <li>DiproSone (MT);</li>\n      <li>Diprotop (TH);</li>\n      <li>Doprosone (AE);</li>\n      <li>Eleuphrat (AU);</li>\n      <li>Hexoderm (PY);</li>\n      <li>Lenovate (ZA);</li>\n      <li>Medobeta (SG, TR);</li>\n      <li>Molason (ID);</li>\n      <li>Novaderm (ZW);</li>\n      <li>Oviskin (ID);</li>\n      <li>Polynovate (TH);</li>\n      <li>Protocort (ID);</li>\n      <li>Repivate (ZA);</li>\n      <li>Soderm (UA);</li>\n      <li>Uniflex (HK, MY);</li>\n      <li>Vitacor (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone dipropionate [prescribing information]. Melville, NY: Fougera Pharmaceuticals, Inc; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone valerate (augmented cream, ointment, and lotion formulations) [prescribing information]. Melville, NY: Fougera; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene AF (augmented betamethasone dipropionate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene AF cream (betamethasone topical) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene lotion (betamethasone topical) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene ointment (betamethasone topical) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, and Kroumpouzos G, &quot;Atopic Dermatitis in Pregnancy: Current Status and Challenges,&quot; <i>Obstet Gynecol Surv</i>, 2011, 66(10):654-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/22112526/pubmed\" target=\"_blank\" id=\"22112526\">22112526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luxiq (betamethasone valerate) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories, Inc; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sernivo spray (betamethasone dipropionate) [prescribing information]. Princeton, NJ: Promius Pharma; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95149 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23780933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23780934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F24168324\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F24168330\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23780990\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F23780936\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24168331\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25090737\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24168325\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F23780928\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F23781007\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23780949\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23780950\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820008\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23781009\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23781008\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F23780945\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23780946\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24168332\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23780956\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F23780958\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F24168333\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23780992\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24799714\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/95149|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=betamethasone-topical-drug-information\" class=\"drug drug_general\">Betamethasone (topical): Drug information</a></li><li><a href=\"topic.htm?path=betamethasone-topical-patient-drug-information\" class=\"drug drug_patient\">Betamethasone (topical): Patient drug information</a></li></ul></div></div>","javascript":null}